Renal function has minimal impact on tirzepatide clearance, as the medication is primarily metabolized through proteolytic pathways rather than renal excretion
The study included 100,455 people in the combination GLP-1RA and SGLT2i group and 339,540 people in the comparison SGLT2i group across 3 cohorts: T2D with atherosclerotic cardiovascular disease (ASCVD), T2D, and T2D with chronic kidney disease (CKD)
ang s dng cc loi thuc khc
The animal literature is unusually consistent, though: nearly every published in vivo study used 5 mg/kg per injection, given three times on alternate days (days 1, 3, and 5, or days 14, 16, and 18 in the pulmonary fibrosis model), with effects tracked over the following three to four weeks
Never accelerate this schedule without medical supervision, as doing so increases the risk and severity of adverse effects, including heartburn
Wang Y, Huang J, Sun Y, Stubbs D, He J, Li W, et al